Herpes Simplex: Global Prevalence Snapshot

Herpes Simplex Virus (HSV) is a prevalent viral infection characterized by the formation of blisters and sores, typically found around the mouth (oral herpes) or the genital region (genital herpes). It is caused by two viral strains: HSV-1 and HSV-2. While the virus can remain dormant within the body for extended periods, it may become reactivated under certain conditions, resulting in recurrent outbreaks. Despite being widespread, there is still a considerable need for more effective antiviral therapies that can minimize outbreak frequency and improve patients’ quality of life.

From prevalence to pipeline—our infographic breaks it down!: Click Here

Herpes Simplex Epidemiological Segmentation

The epidemiological breakdown of Herpes Simplex in the 7MM from 2020 to 2034 includes the following:

• Total seroprevalent cases of HSV

• Total symptomatic cases of HSV

• Total diagnosed cases of HSV

• Gender-specific diagnosed cases of HSV

• Total recurrent cases of HSV

Herpes Simplex Epidemiology

In 2023, the epidemiological landscape of Herpes Simplex revealed distinct patterns across the 7MM:

• An estimated 13.04 million diagnosed cases of HSV were recorded across the 7MM, with around 4.95 million of those cases occurring in the United States. This figure is projected to decline over the forecast period.

• Female-diagnosed cases exceeded those in males across the 7MM, with women accounting for approximately 55% of total diagnosed cases.

• In Japan, about 1.56 million diagnosed cases were reported in 2023, including 700,000 males and 856,000 females. These numbers are also expected to decrease during the study period.

Numbers tell part of the story—get the full analysis in our report: [Click Here

](https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr)

Herpes Simplex Market

The overall market size for Herpes Simplex across the 7MM was approximately USD 3.1 billion in 2023.

Herpes Simplex Market Drivers

• The development of novel antiviral drugs such as PRITELIVIR (AIC-316) and mRNA-1608 provides promising opportunities for better HSV management and reduced outbreak recurrence.

• Increased public awareness and advancements in diagnostic techniques are expected to boost the identification and treatment of symptomatic HSV infections, thereby driving market expansion.

Herpes Simplex Market Barriers

• Variability in HSV flare-ups and differences in patient response to treatment make consistent disease management and the development of universal therapies challenging.

• High costs and limited accessibility of innovative antiviral drugs may hinder broad adoption, especially in low-resource settings, creating obstacles to market growth.

Herpes Simplex Emerging Therapies

• PRITELIVIR (AIC-316)

• GSK3943104

• mRNA-1608

• And others

Grab your free copy of the infographic—essential for any analyst!: [**Click Here

**](https://www.delveinsight.com/infographics/herpes-simplex-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr)

Herpes Simplex Key Players

• AiCuris Anti-infective Cures AG

• GlaxoSmithKline

• ModernaTX, Inc.

And others